CEL-SCI plans to start patient enrollment in summer 2026 for a 212-patient U.S. registration study of its cancer immunotherapy Multikine, with the goal of seeking early accelerated approval. The company is also advancing a strategic partnership with Saudi Amarox to commercialize Multikine in Saudi Arabia, where it has submitted a Breakthrough Medicine Designation application. These initiatives build on Phase 3 data showing Multikine improved 5-year survival in head and neck cancer patients from 45% to 73%.
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
Researchers have engineered immune cells to sense cancer metabolites, improving tumor infiltration in solid cancers. Separate studies identify Kappa and Lambda Myeloma Antigens as specific targets for multiple myeloma treatment, while mRNA-based personalized cancer vaccines show promise through AI-driven neoantigen selection.
Prognica Labs and NextGen Immuno Therapeutics announced a strategic partnership to advance AI-powered immune diagnostics and personalized medicine across the GCC, India, and the United States, targeting oncology, transplant medicine, and autoimmune disorders.
A study published in Nature Microbiology demonstrates that a defined consortium of 15 gut bacterial species derived from immunotherapy responders significantly enhances anti-PD-1 treatment efficacy in mouse models of non-small-cell lung cancer.
Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025 and acquired Orna Therapeutics for $2.4 billion to develop circular RNA therapies for autoimmune diseases.
Eli Lilly acquired Orna Therapeutics for $2.4 billion and announced multiple partnerships while investing in AI drug discovery infrastructure, including building the industry's largest AI supercomputer to boost clinical trial success rates.
